© 2020 MJH Life Sciences and Urology Times. All rights reserved.
OAB and Incontinence
Nerve stim device provides long-term OAB symptom improvement
December 10, 2018
An investigational wireless, implantable tibial nerve stimulator is safe and provided improvement in overactive bladder symptoms over 3 years of follow-up.
Beta-3 agonist shows benefit for OAB in older adults
December 10, 2018
Mirabegron (Myrbetriq) is effective and well tolerated in patients age 65 or older with overactive bladder, results of a randomized, placebo-controlled study show.
OAB patients continue medical therapy unnecessarily
November 20, 2018
A recent study found that sacral neuromodulation monotherapy was efficacious as a third-line treatment.
Nearly 30% of U.S. women report nocturia
November 20, 2018
Nocturia appears to be highly prevalent in the United States, with almost 30% of all women reporting significant nocturia, according to new data reported at the AUA annual meeting in San Francisco.
Data shift thinking on nocturia’s causes, treatment
November 20, 2018
Waking up at night to urinate is by far the most bothersome lower urinary tract symptom.
Non-head MRI found safe in patients undergoing SNM
November 07, 2018
The therapeutic efficacy of sacral neuromodulation was not affected by non-head magnetic resonance imaging scans in a recent study.
More than 50% of patients stop botulinum treatment
November 07, 2018
Over half of patients stop intradetrusor botulinum toxin injections within 10 years, mostly due to lack of clinical efficacy, researchers say.
Large datasets shed light on benign urologic conditions
November 06, 2018
In this interview, J. Quentin Clemens, MD, discusses the work being done by the MAPP (Multidisciplinary Approach to Chronic Pelvic Pain) Research Network and LURN (Symptoms of Lower Urinary Tract Dysfunction Research Network) research initiatives.
Nocturia treatment efficacious after single dose
November 01, 2018
“The results suggest that this compound has rapid efficacy and a favorable safety profile in patients with nocturia due to nocturnal polyuria,” says researcher Diane Newman, DNP.
Botulinum toxin more cost-effective than SNM
November 01, 2018
Cost-effectiveness results favored botulinum toxin at 2 years as well as in an analysis at 5 years accounting for increased cost of the botulinum approach due to repeat injections, according to investigator Heidi S. Harvie, MD, MSCE.